GlassScriptPhysician profile
Solomiya Grushchak
NPI 1588168108
$2,895.35
in general payments reported to CMS, 2019-2025
18 companies · $711 in 2025
The $711 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $225 · 2021: $414 · 2022: $329 · 2023: $111 · 2024: $724 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.17 |
| Education | $123.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,132.36 | 2019-2025 | |
| Galderma Laboratories, L.P. | $335.32 | 2021-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $237.13 | 2020-2022 | |
| Janssen Biotech, INC. | $220.89 | 2024 | Tremfya |
| Genzyme Corporation | $172.25 | 2019-2025 | |
| Celgene Corporation | $124.55 | 2019 | |
| Arcutis Biotherapeutics, INC. | $120.14 | 2023-2025 | Zoryve |
| Organon LLC | $113.27 | 2025 | Vtama |
| Incyte Corporation | $80.93 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $76.31 | 2024-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $74.93 | 2020-2025 | Taltz, Ebglyss |
| Pfizer INC. | $56.89 | 2024 | |
| Journey Medical Corporation | $42.01 | 2021 | |
| Ucb, INC. | $25.87 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.47 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $22.31 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.33 | 2024 | Spevigo |
| Amgen INC. | $17.39 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solomiya Grushchak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.